CLINICALLY PREDICTIVE MODULATION OF COGNITIVE IMPAIRMENTS IN MOUSE TOUCHSCREEN TASKS

Abstract Background Cognitive deficits in individuals with schizophrenia present a significant barrier to maintaining interpersonal relationships, employment, and independent living. Moderate to severe impairments have been found in cognitive domains including working memory, attention, learning and executive function. Despite the clear impact on functional outcomes, there are currently no approved treatments for cognitive impairments associated with schizophrenia (CIAS). Extensive efforts to develop pro-cognitive medicines, both for CIAS and other neuropsychiatric disorders, have repeatedly led to clinical trials that do not reflect the efficacy predicted in preclinical models. Aims & Objectives The rodent touchscreen platform has begun to bridge the translational gap between preclinical and clinical assessments of cognitive function. However, to date there has been no pharmacological validation of whether these tests are stringent enough to be clinically predictive and can therefore improve translation of CIAS treatments. Method Here, we use an NMDA receptor antagonist mouse model (acute low-dose administration) that we have validated for cognitive deficits in working memory performance on the rodent trial-unique delayed nonmatch-to-location touchscreen task. We then measured the effect of 1) current standard of care (aripiprazole and olanzapine), 2) failed investigational new drugs (IND) for CIAS (atomoxetine and encenicline), and 3) a current IND for schizophrenia (xanomeline) on working memory and attentional impairments. Results For the first time, we demonstrate a translational method for cognitive assessment in mice that can distinguish drugs with clinical efficacy from those without. Discussion & Conclusion These results provide critical insight into the predictive validity of our preclinical assay and cognitive deficit model, and have significant implications for the development and translation of novel pro-cognitive medicines.

Authors

Institutions

Publication Details

Journal
The International Journal of Neuropsychopharmacology
Published
2025-02-01
DOI
https://doi.org/10.1093/ijnp/pyae059.088
Primary Topic
Creativity in Education and Neuroscience
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CLINICALLY PREDICTIVE MODULATION OF COGNITIVE IMPAIRMENTS IN MOUSE TOUCHSCREEN TASKS

Leonid P. Churilov, Daisy L. Spark, Trang Pham, Michelle A. Camerino et al.
The International Journal of Neuropsychopharmacology
Creativity in Education and Neuroscience
article

CLINICALLY PREDICTIVE MODULATION OF COGNITIVE IMPAIRMENTS IN MOUSE TOUCHSCREEN TASKS

Leonid P. Churilov, Daisy L. Spark, Trang Pham, Michelle A. Camerino, Gregory D. Stewart, Christopher J. Langmead, Jess Nithianantharajah, Juulke Castelijn
article en

Abstract

Abstract Background Cognitive deficits in individuals with schizophrenia present a significant barrier to maintaining interpersonal relationships, employment, and independent living. Moderate to severe impairments have been found in cognitive domains including working memory, attention, learning and executive function. Despite the clear impact on functional outcomes, there are currently no approved treatments for cognitive impairments associated with schizophrenia (CIAS). Extensive efforts to develop pro-cognitive medicines, both for CIAS and other neuropsychiatric disorders, have repeatedly led to clinical trials that do not reflect the efficacy predicted in preclinical models. Aims & Objectives The rodent touchscreen platform has begun to bridge the translational gap between preclinical and clinical assessments of cognitive function. However, to date there has been no pharmacological validation of whether these tests are stringent enough to be clinically predictive and can therefore improve translation of CIAS treatments. Method Here, we use an NMDA receptor antagonist mouse model (acute low-dose administration) that we have validated for cognitive deficits in working memory performance on the rodent trial-unique delayed nonmatch-to-location touchscreen task. We then measured the effect of 1) current standard of care (aripiprazole and olanzapine), 2) failed investigational new drugs (IND) for CIAS (atomoxetine and encenicline), and 3) a current IND for schizophrenia (xanomeline) on working memory and attentional impairments. Results For the first time, we demonstrate a translational method for cognitive assessment in mice that can distinguish drugs with clinical efficacy from those without. Discussion & Conclusion These results provide critical insight into the predictive validity of our preclinical assay and cognitive deficit model, and have significant implications for the development and translation of novel pro-cognitive medicines.

The International Journal of NeuropsychopharmacologyVol. 28(Supplement_1)
The University of Melbourne (AU), Florey Institute of Neuroscience and Mental Health (AU), Discovery Institute (US), Australian Regenerative Medicine Institute (AU), Monash Medical Centre (AU), Phelix Therapeutics (United States) (US), Monash University (AU)
Openalex Percentile: Top 98%
Creativity in Education and Neuroscience
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.